Retatrutide is the newest, triple-action option, targeting GLP-1, GIP, and glucagon for the strongest results in early studies
Why Do They Occur on GLP-1 Medications
DailyMed - ADLYXIN- lixisenatide kit adlyxin- lixisenatide injection, solution
Follow the recommended dosing protocol rather than trying to accelerate results by increasing doses faster than recommended
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2, NEJM , 2023 ClinicalTrials.gov TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367) FDA Wegovy prescribing information, 2025 FDA Zepbound (tirzepatide) prescribing information, 2024 Medical disclaimer: This article is for informational purposes only
It was approved in 2024